Drugs / CD19 PD-1/CD28 CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04850560 | May 2021 → May 2022 | — | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19 PD-1/CD28 CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04850560 ↗ |
| Modality | Cell therapy | “CD19 PD-1/CD28 CAR-T” NCT04850560 ↗ |
| Target | CD19 | “CD19 PD-1/CD28 CAR-T” NCT04850560 ↗ |